Skip to main content
Top
Published in: Clinical and Experimental Nephrology 3/2012

01-06-2012 | Case Report

Accelerated recovery from nephrotic syndrome with acute renal failure by double filtration plasmapheresis in a patient with lupus podocytopathy

Authors: Yoshitaka Iwazu, Tetsu Akimoto, Sayoko Izawa, Makoto Inoue, Shigeaki Muto, Yasuhiro Ando, Kana Iwazu, Noriyoshi Fukushima, Wako Yumura, Eiji Kusano

Published in: Clinical and Experimental Nephrology | Issue 3/2012

Login to get access

Abstract

We describe a case of an adult female who presented with nephrotic syndrome. She was diagnosed with systemic lupus erythematosus with serum antinuclear antibodies, leucopenia with lymphopenia, butterfly erythema, and nephrotic syndrome. Renal biopsy revealed normal glomeruli with diffuse effacement of the foot processes, consistent with lupus podocytopathy. Although human albumin replacement was performed initially, acute renal failure developed rapidly. Therefore, she was treated with double filtration plasmapheresis (DFPP) in addition to oral steroid. After steroid therapy combined with DFPP, the renal function and proteinuria improved rapidly. Although the impact of DFPP on the treatment of lupus nephritis remains to be delineated, our observations suggest that DFPP in lupus podocytopathy played a pivotal role in facilitating the early recovery from renal injuries. Because of the rapid improvement of renal function without any change in body weight by DFPP, acute renal failure in the setting of lupus podocytopathy might contribute to an alternative pathophysiological factor for the diminished glomerular filtration rate, similar to that observed in the setting of idiopathic minimal change glomerulopathy.
Literature
1.
go back to reference Dube GK, Markowitz GS, Randhakrishnan J, Appel GB, D’Agati VD. Minimal change disease in systemic lupus erythematosus. Clin Nephrol. 2002;57:120–6.PubMed Dube GK, Markowitz GS, Randhakrishnan J, Appel GB, D’Agati VD. Minimal change disease in systemic lupus erythematosus. Clin Nephrol. 2002;57:120–6.PubMed
2.
go back to reference Hertig A, Droz D, Lesavre P, Grunfeld JP, Rieu P. SLE and idiopathic nephrotic syndrome: coincidence or not? Am J Kidney Dis. 2002;40:1179–84.PubMedCrossRef Hertig A, Droz D, Lesavre P, Grunfeld JP, Rieu P. SLE and idiopathic nephrotic syndrome: coincidence or not? Am J Kidney Dis. 2002;40:1179–84.PubMedCrossRef
3.
go back to reference Kraft SW, Schwartz MM, Korbet SM, Lewis EJ. Glomerular podocytopathy in patients with systemic lupus erythematosus. J Am Soc Nephrol. 2005;16:175–9.PubMedCrossRef Kraft SW, Schwartz MM, Korbet SM, Lewis EJ. Glomerular podocytopathy in patients with systemic lupus erythematosus. J Am Soc Nephrol. 2005;16:175–9.PubMedCrossRef
4.
go back to reference Masuda T, Akimoto T, Ando Y, Kobayashi T, Meguro D, Muto S, et al. Changes in the urinary excretion of beta2-microglobulin (beta 2MG) and N-acetyl-beta-d-glucosaminidase (NAG) during treatment for lupus nephritis. Intern Med. 2008;47:287–90.PubMedCrossRef Masuda T, Akimoto T, Ando Y, Kobayashi T, Meguro D, Muto S, et al. Changes in the urinary excretion of beta2-microglobulin (beta 2MG) and N-acetyl-beta-d-glucosaminidase (NAG) during treatment for lupus nephritis. Intern Med. 2008;47:287–90.PubMedCrossRef
5.
go back to reference Danieli MG, Palmieri C, Salvi A, Refe MC, Strusi AS, Danieli G. Synchronised therapy and high-dose cyclophosphamide in proliferative lupus nephritis. J Clin Apher. 2002;17:72–7.PubMedCrossRef Danieli MG, Palmieri C, Salvi A, Refe MC, Strusi AS, Danieli G. Synchronised therapy and high-dose cyclophosphamide in proliferative lupus nephritis. J Clin Apher. 2002;17:72–7.PubMedCrossRef
6.
go back to reference Huang DF, Tsai ST, Wang SR. Recovery of both acute massive pulmonary hemorrhage and acute renal failure in a systemic lupus erythematosus patient with lupus anticoagulant by the combined therapy of plasmapheresis plus cyclophosphamide. Transfus Sci. 1994;15:283–8.PubMedCrossRef Huang DF, Tsai ST, Wang SR. Recovery of both acute massive pulmonary hemorrhage and acute renal failure in a systemic lupus erythematosus patient with lupus anticoagulant by the combined therapy of plasmapheresis plus cyclophosphamide. Transfus Sci. 1994;15:283–8.PubMedCrossRef
7.
go back to reference Sulowicz W, Stompór T. LDL-apheresis and immunoadsorption: novel methods in the treatment of renal diseases refractory to conventional therapy. Nephrol Dial Transplant. 2003;18(Suppl 5):v59–62.PubMedCrossRef Sulowicz W, Stompór T. LDL-apheresis and immunoadsorption: novel methods in the treatment of renal diseases refractory to conventional therapy. Nephrol Dial Transplant. 2003;18(Suppl 5):v59–62.PubMedCrossRef
8.
go back to reference Braun N, Erley C, Klein R, Kötter I, Saal J, Risler T. Immunoadsorption onto protein A induces remission in severe systemic lupus erythematosus. Nephrol Dial Transplant. 2000;15:1367–72.PubMedCrossRef Braun N, Erley C, Klein R, Kötter I, Saal J, Risler T. Immunoadsorption onto protein A induces remission in severe systemic lupus erythematosus. Nephrol Dial Transplant. 2000;15:1367–72.PubMedCrossRef
9.
go back to reference Pfueller B, Wolbart K, Bruns A, Burmester GR, Hiepe F. Successful treatment of patients with systemic lupus erythematosus by immunoadsorption with a C1q column: a pilot study. Arthritis Rheum. 2001;44:1962–3.PubMedCrossRef Pfueller B, Wolbart K, Bruns A, Burmester GR, Hiepe F. Successful treatment of patients with systemic lupus erythematosus by immunoadsorption with a C1q column: a pilot study. Arthritis Rheum. 2001;44:1962–3.PubMedCrossRef
10.
go back to reference Stummvoll GH, Aringer M, Smolen JS, Schmaldienst S, Jiménez-Boj E, Hörl WH, et al. IgG immunoadsorption reduces systemic lupus erythematosus activity and proteinuria: a long term observational study. Ann Rheum Dis. 2005;64:1015–21.PubMedCrossRef Stummvoll GH, Aringer M, Smolen JS, Schmaldienst S, Jiménez-Boj E, Hörl WH, et al. IgG immunoadsorption reduces systemic lupus erythematosus activity and proteinuria: a long term observational study. Ann Rheum Dis. 2005;64:1015–21.PubMedCrossRef
11.
go back to reference Nakamura T, Ushiyama C, Hara M, Osada S, Ugai K, Shimada N, et al. Comparative effects of plasmapheresis and intravenous cyclophosphamide on urinary podocyte excretion in patients with proliferative lupus nephritis. Clin Nephrol. 2002;57:108–13.PubMed Nakamura T, Ushiyama C, Hara M, Osada S, Ugai K, Shimada N, et al. Comparative effects of plasmapheresis and intravenous cyclophosphamide on urinary podocyte excretion in patients with proliferative lupus nephritis. Clin Nephrol. 2002;57:108–13.PubMed
12.
go back to reference Endo S, Inada K, Nakae H, Takakuwa T, Kasai T, Yamada Y, et al. Blood levels of endothelin-1 and thrombomodulin in patients with disseminated intravascular coagulation and sepsis. Res Commun Mol Pathol Pharmacol. 1995;90:277–88.PubMed Endo S, Inada K, Nakae H, Takakuwa T, Kasai T, Yamada Y, et al. Blood levels of endothelin-1 and thrombomodulin in patients with disseminated intravascular coagulation and sepsis. Res Commun Mol Pathol Pharmacol. 1995;90:277–88.PubMed
13.
go back to reference Boehme MW, Nawroth PP, Kling E, Lin J, Amiral J, Riedesel J, et al. Serum thrombomodulin. A novel marker of disease activity in systemic lupus erythematosus. Arthritis Rheum. 1994;37:572–7.PubMedCrossRef Boehme MW, Nawroth PP, Kling E, Lin J, Amiral J, Riedesel J, et al. Serum thrombomodulin. A novel marker of disease activity in systemic lupus erythematosus. Arthritis Rheum. 1994;37:572–7.PubMedCrossRef
14.
go back to reference Boehme MWJ, Raeth U, Galle PR, Stremmel W, Scherbaum WA. Serum thrombomodulin—a reliable marker of disease activity in systemic lupus erythematosus (SLE): advantage over established serological parameters to indicate disease activity. Clin Exp Immunol. 2000;119:189–95.PubMedCrossRef Boehme MWJ, Raeth U, Galle PR, Stremmel W, Scherbaum WA. Serum thrombomodulin—a reliable marker of disease activity in systemic lupus erythematosus (SLE): advantage over established serological parameters to indicate disease activity. Clin Exp Immunol. 2000;119:189–95.PubMedCrossRef
15.
go back to reference Frijns R, Fijnheer R, Schiel A, Donders R, Sixma J, Derksen R. Persistent increase in plasma thrombomodulin in patients with a history of lupus nephritis: endothelial cell activation markers. J Rheumatol. 2001;28:514–9.PubMed Frijns R, Fijnheer R, Schiel A, Donders R, Sixma J, Derksen R. Persistent increase in plasma thrombomodulin in patients with a history of lupus nephritis: endothelial cell activation markers. J Rheumatol. 2001;28:514–9.PubMed
16.
go back to reference Ho CY, Wong CK, Li EK, Tam LS, Lam CWK. Elevated plasma concentrations of nitric oxide, soluble thrombomodulin and soluble vascular cell adhesion molecule-1 in patients with systemic lupus erythematosus. Rheumatology. 2003;42:117–22.PubMedCrossRef Ho CY, Wong CK, Li EK, Tam LS, Lam CWK. Elevated plasma concentrations of nitric oxide, soluble thrombomodulin and soluble vascular cell adhesion molecule-1 in patients with systemic lupus erythematosus. Rheumatology. 2003;42:117–22.PubMedCrossRef
17.
go back to reference Shea-Simonds P, Cairns TD, Roufosse C, Cook T, Vyse TJ. Lupus podocytopathy. Rheumatology. 2009;48:1616–8.PubMedCrossRef Shea-Simonds P, Cairns TD, Roufosse C, Cook T, Vyse TJ. Lupus podocytopathy. Rheumatology. 2009;48:1616–8.PubMedCrossRef
18.
go back to reference Horino T, Takao T, Morita T, Ito H, Hashimoto K. Minimal change nephrotic syndrome associated with systemic lupus erythematosus. Nephrol Dial Transplant. 2006;21:230.PubMedCrossRef Horino T, Takao T, Morita T, Ito H, Hashimoto K. Minimal change nephrotic syndrome associated with systemic lupus erythematosus. Nephrol Dial Transplant. 2006;21:230.PubMedCrossRef
19.
go back to reference Deji N, Sugimoto T, Kanasaki M, Aoyama M, Tanaka Y, Sakaguchi M, et al. Emerging minimal-change nephrotic syndrome in a patient with chronic mesangial proliferative lupus nephritis. Intern Med. 2007;46:991–5.PubMedCrossRef Deji N, Sugimoto T, Kanasaki M, Aoyama M, Tanaka Y, Sakaguchi M, et al. Emerging minimal-change nephrotic syndrome in a patient with chronic mesangial proliferative lupus nephritis. Intern Med. 2007;46:991–5.PubMedCrossRef
20.
go back to reference Seo DB, Lee SW, Song JH, Lee KJ, Han JY, Kim MJ. Acute renal failure associated with a minimal change nephrotic syndrome in a systemic lupus erythematosus patient. Yonsei Med J. 2002;43:114–8.PubMed Seo DB, Lee SW, Song JH, Lee KJ, Han JY, Kim MJ. Acute renal failure associated with a minimal change nephrotic syndrome in a systemic lupus erythematosus patient. Yonsei Med J. 2002;43:114–8.PubMed
21.
go back to reference Cameron MA, Peri U, Rogers TE, Moe OW. Minimal change disease with acute renal failure: a case against the nephrosarca hypothesis. Nephrol Dial Transplant. 2004;19:2642–6.PubMedCrossRef Cameron MA, Peri U, Rogers TE, Moe OW. Minimal change disease with acute renal failure: a case against the nephrosarca hypothesis. Nephrol Dial Transplant. 2004;19:2642–6.PubMedCrossRef
22.
go back to reference Libit SA, Burke BA, Michael AF, Vernier RL. Extramembranous glomerulonephritis in childhood: relationship to systemic lupus erythematosus. J Pediatr. 1976;88:394–402.PubMedCrossRef Libit SA, Burke BA, Michael AF, Vernier RL. Extramembranous glomerulonephritis in childhood: relationship to systemic lupus erythematosus. J Pediatr. 1976;88:394–402.PubMedCrossRef
23.
go back to reference Shearn MA, Hopper J, Biava CG. Membranous lupus nephropathy initially seen as idiopathic membranous nephropathy. Possible diagnostic value of tubular reticular structures. Arch Intern Med. 1980;140:1521–3.PubMedCrossRef Shearn MA, Hopper J, Biava CG. Membranous lupus nephropathy initially seen as idiopathic membranous nephropathy. Possible diagnostic value of tubular reticular structures. Arch Intern Med. 1980;140:1521–3.PubMedCrossRef
24.
go back to reference Feldman D, Goldstein AL, Cox DC, Grimley PM. Cultured human endothelial cells treated with recombinant leukocyte A interferon. Tubuloreticular inclusion formation, antiproliferative effect, and 2′,5′ oligoadenylate synthetase induction. Lab Invest. 1988;58:584–9.PubMed Feldman D, Goldstein AL, Cox DC, Grimley PM. Cultured human endothelial cells treated with recombinant leukocyte A interferon. Tubuloreticular inclusion formation, antiproliferative effect, and 2′,5′ oligoadenylate synthetase induction. Lab Invest. 1988;58:584–9.PubMed
25.
go back to reference Venkataseshan VS, Marquet E, Grishman E. Significance of cytoplasmic inclusions in lupus nephritis. Ultrastruct Pathol. 1991;15:1–14.PubMedCrossRef Venkataseshan VS, Marquet E, Grishman E. Significance of cytoplasmic inclusions in lupus nephritis. Ultrastruct Pathol. 1991;15:1–14.PubMedCrossRef
26.
go back to reference Jennette JC, Iskandar SS, Dalldorf FG. Pathologic differentiation between lupus and nonlupus membranous glomerulopathy. Kidney Int. 1983;24:377–85.PubMedCrossRef Jennette JC, Iskandar SS, Dalldorf FG. Pathologic differentiation between lupus and nonlupus membranous glomerulopathy. Kidney Int. 1983;24:377–85.PubMedCrossRef
Metadata
Title
Accelerated recovery from nephrotic syndrome with acute renal failure by double filtration plasmapheresis in a patient with lupus podocytopathy
Authors
Yoshitaka Iwazu
Tetsu Akimoto
Sayoko Izawa
Makoto Inoue
Shigeaki Muto
Yasuhiro Ando
Kana Iwazu
Noriyoshi Fukushima
Wako Yumura
Eiji Kusano
Publication date
01-06-2012
Publisher
Springer Japan
Published in
Clinical and Experimental Nephrology / Issue 3/2012
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-012-0606-6

Other articles of this Issue 3/2012

Clinical and Experimental Nephrology 3/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.